Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-02-17
Target enrollment:
Participant gender:
Summary
This first-time-in-human (FTIH) study will evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating
doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants
with advanced solid tumors. This study will be used to define the recommended Phase 2 dose
(RP2D). The study comprises 3 phases; screening phase (28 days prior to first dose),
treatment phase (until disease progression, unacceptable toxicity, death, or withdrawal of
consent) and follow-up phase (90 days). Approximately 100 adult participants with locally
advanced, recurrent, or metastatic solid tumors will be enrolled.